AvaALL: Open-Label Randomized Phase 1Mb Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Continuous Bevacizumab (BV) Treatment Beyond Disease Progression in Patients (pts) With Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) After First-Line (1L) Treatment With BV Plus Platinum-Doublet Chemotherapy (CT)

摘要

Prognosis and survival rates are very poor for patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed after first-line chemotherapy.1 However, the failure of chemotherapy does not necessarily imply that anti-angiogenesis will fail.2 Although the disease may have progressed on chemotherapy, vascular endothelial growth factor (VEGF) is a key factor in tumor angiogenesis that is present and stable throughout the tumor life cycle, and it is targeted by bevacizumab. Chemotherapy fails primarily due to disease resistance from genetic instabilities, but antiangiogenic signaling continues throughout the disease lifespan and tumors may still depend on VEGE